UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ______________________ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charte ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants John Bluth - Senior Vice President, Investor Relations & Corporate Communications Jon Stonehouse - Chief Executive Officer Charlie Gayer - Chief Commercial Officer Megan Sniecinski - Chief Business Officer Bill Sheridan - Chief Medical Officer Anthony Doyle - Chief Financial Officer Conference Call Participants Tara Bancroft - Piper Sandler Jon Wolleben - JMP Securities Serge Bela ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________. Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (Stateorotherjurisd ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants John Bluth - Senior Vice President, Investor Relations & Corporate Communications Jon Stonehouse - President & Chief Executive Officer Charlie Gayer - Chief Commercial Officer Megan Sniecinski - Chief Business Officer William Sheridan - Chief Medical Officer Anthony Doyle - Chief Financial Officer Conference Call Participants Tyler Van Buren - Piper Sandler David Dai - Barclays Jonath ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 62-1413174 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 4505 Emperor Blvd., Suite 200 Durham, North Carolina 2770 ...